NCT02897778 - Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 24, 2016

Primary Completion Date

March 13, 2017

Study Completion Date

March 13, 2017

Conditions

NeoplasmsNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsDigestive System NeoplasmsEndocrine Gland NeoplasmsCarcinoma, Non-Small-Cell LungLung DiseasesBreast NeoplasmsBreast DiseasesRenal NeoplasmSolid Tumors

Interventions

DRUG

Entinostat

Single, supratherapeutic dose of entinostat given orally.

DRUG

Placebo

Single dose of placebo-matching entinostat (containing inactive ingredients matching the appearance of the active product).

Trial Locations (1)

78229

The START Center for Cancer Care, San Antonio